Patents Examined by Robert S. Landsman
  • Methods of diagnosing and treating cervical cancer or a high-grade cervical lesion based on expression of ankyrin-3
    Patent number: 11160845
    Abstract: The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: November 2, 2021
    Assignee: Timser, S.A.P.I. de C.V.
    Inventors: Alberto Checa Rojas, Orlando Santillan Godinez, Raul Dominguez Palestino
  • Methods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase
    Patent number: 11160844
    Abstract: The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: November 2, 2021
    Assignee: Timser, S.A.P.I. de C.V.
    Inventors: Alberto Checa Rojas, Orlando Santillan Godinez, Raul Dominguez Palestino
  • Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5
    Patent number: 11155593
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: October 26, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety
    Patent number: 11149083
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: October 19, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
    Patent number: 11149075
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 19, 2021
    Assignee: APOGENIX AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
    Patent number: 11142558
    Abstract: The present invention relates to a tumor necrosis factor receptor (TNFR) binding protein complex comprising 12 or more protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR. Preferably, the TNFR binding protein complex binds to the extracellular part of TNFR2. Preferably, the TNFR binding protein complex of the present invention further comprises two or more polymerization domains (PD).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: October 12, 2021
    Inventors: Roman Fischer, Roland Kontermann, Klaus Pfizenmaier, Martin Siegemund
  • Anti-human nicotinamide phosphoribosyltransferase (NAMPT) antibodies
    Patent number: 11142586
    Abstract: Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies, or antigen binding fragments thereof, are described, as well as methods for treating a subject having a (NAMPT)-associated local and/or systemic inflammatory disorder.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 12, 2021
    Assignee: Aqualung Therapeutics
    Inventors: Joe G. N. Garcia, Darragh MacCann
  • Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer
    Patent number: 11142588
    Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 12, 2021
    Assignee: ADALTA LIMITED
    Inventors: Michael Foley, Andrew Pow, Katherine Griffiths, Samantha Cobb, Katerina Viduka
  • Antibodies that specifically bind alpha klotho
    Patent number: 11143661
    Abstract: An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining region (CDR) CDR-L3 and the heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs comprising one or more of the sequences set forth below: CDR-L3; selected from any one of SEQ ID NOs: 123, 126-130, 142, 148 or 149; CDR-H1: SEQ ID NOs: 121 or 124; CDR-H2; SEQ ID NOs: 122 or 125; and/or CDR-H3: selected from any one of SEQ ID NOs: 196-226.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: October 12, 2021
    Assignees: The Governing Council of the University of Toronto, Board of Regents, The University of Texas System
    Inventors: Sachdev S. Sidhu, Sarah L. Barker, Orson W. Moe, Makoto Kuro-o, Johanne Pastor
  • Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
    Patent number: 11136386
    Abstract: Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: October 5, 2021
    Assignees: PROMETHEUS BIOSCIENCES, INC., CEDARS-SINAI MEDICAL CENTER
    Inventors: Laurens Kruidenier, Mahyar Sabripour, Janine Bilsborough, Dermot P. McGovern, Dalin Li
  • Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
    Patent number: 11136385
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: October 5, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Humanized monoclonal antibodies that target VE-PTP (HPTP-?)
    Patent number: 11136389
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 5, 2021
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Methods of using thermally expanded graphite to remove proteins from blood and to treat sepsis
    Patent number: 11123465
    Abstract: The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: September 21, 2021
    Assignee: Drexel University
    Inventors: Yury Gogotsi, Vadym Mochalin, Nicholas Pescatore
  • Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2)
    Patent number: 11111304
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Conjugates comprising a vascular endothelial growth factor (VEGF) antibody and a hyaluronic acid polymer
    Patent number: 11111291
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 7, 2021
    Assignee: Genetech, Inc.
    Inventors: Amin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
  • Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
    Patent number: 11111305
    Abstract: This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 7, 2021
    Assignee: TORCH THERAPEUTICS
    Inventors: Todd M. Kinsella, Donald G. Payan, Ramesh Bhatt, Kristen Baltgalvis
  • Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4
    Patent number: 11111309
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: September 7, 2021
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
  • Composition comprising a lyophilized detergent-solubilized protein
    Patent number: 11104717
    Abstract: A method for generating detergent-solubilized G-protein coupled receptors (GPCRs) in powdered form. The powdered GPCRs is storable at temperatures of ?20° C. or lower and for durations of 365 days or longer without substantial loss of functionality of the GPCRs after rehydration as compared to a pre-frozen state. The method can maintain minimal detergent to protein ratio in molar concentrations. The method can further generate GPCRs with specific water or deuterium content as required in certain experiments, such as mass spectrometry, NMR spectroscopy, or quasi-elastic neutron scattering (QENS).
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 31, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Michael F. Brown, Suchithranga Perera, Udeep Chawla
  • Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3
    Patent number: 11098111
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 24, 2021
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition
    Patent number: 11090335
    Abstract: A chimeric antigen receptor targeting to human NKG2DL, its encoding sequence, and its modified immune response cells, and the preparation and application thereof are provided. This invention constructs a chimeric antigen receptor targeting to NKG2DL and its modified immune response cell based on the NKG2D molecule. The amino acid sequence of the chimeric antigen receptor targeting the human NKG2DL is sequentially connected by the following amino acid sequences from an amino terminal to a carboxy terminal: an amino acid sequence of a guiding sequence, an amino acid sequence of human NKG2D, an amino acid sequence of a human CD8 hinge region, an amino acid sequence of a human CD8 transmembrane region, an amino acid sequence of a human 4-1BB intracellular domain and an amino acid sequence of a human CD3 zeta domain.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: August 17, 2021
    Assignee: NANJING KAEDI BIOTHERAPEUTICS LTD.
    Inventors: Hongjiu Dai, Bin Sun, Xudong Zhao